Arbutus Biopharma Corporation Stock Earnings Reports
ABUS Upcoming Earnings (Q3 2023)
Earnings Date: | Nov 07, 2023 |
Consensus EPS: | Premium |
Current P/E* ratio: -4.63 | Price (Sep 29, 2023, EOD): $2.03
*The P/E ratio (price-to-earnings ratio) is a financial metric used to assess a company's stock valuation. It is calculated by dividing the stock price by its earnings per share. A higher ratio suggests higher investor expectations, while a lower ratio may indicate undervaluation. It helps investors evaluate potential investments, but it's essential to consider other factors too.
Last 3 Quarters for ABUS Premium
FAQ
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.